2023年4月13日 · PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC.

Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC). Limited data are available about its utility in discriminating neoplastic from regenerative nodules at ultrasonography (US) evaluation in cirrhotic patients.

Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. ...

elecsys pivka-ii and elecsys afp assays demonstrate good clinical performance for hepatocellular carcinoma (hcc) diagnosis across different disease stages and etiologies. In The Liver Meeting Digital Experience™.

PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II) is a protein-based biomarker used to detect liver cancer in its early stages. This test is more effective than AFP alone in diagnosing hepatocellular carcinoma.

2021年9月30日 · Multi-center study showed the satisfactory diagnostic performance of PIVKA-II in hepatocellular carcinoma. PIVKA-II has excellent specificity in distinguishing benign liver diseases. The distribution...

2021年4月13日 · PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC.

The current work was designed to determine the level of prothrombin induced by vitamin K absence-II (PIVKA-II) in sera of patients suffering from HCC and hepatitis C virus (HCV) patients being the most common predisposing factor for HCC.

2017年9月1日 · Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied.

Background & aims: Prothrombin induced by vitamin K absence-II (PIVKA-II) is a diagnostic and surveillance marker for HCC mainly used in Asia, and has also been shown to be a predictor of microvascular invasion (MVI), a major prognostic factor in HCC. However, experience with PIVKA-II in Europe remains limited.

Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker.

2022年12月1日 · Protein induced by vitamin K absence or antagonist II (PIVKA-II) is a well-accepted biomarker for diagnosing hepatocellular carcinoma (HCC). Although nonspecific increase of PIVKA-II has been reported, real-world evidence remains scarce.

2021年11月23日 · Prothrombin induced by vitamin K absence II (PIVKA-II) has recently been validated internationally as a diagnostic biomarker for hepatocellular carcinoma (HCC), as part of the GALAD model. However, its role as a treatment …

2021年4月13日 · PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC. The PIVKA-II levels in HCC patients were widely associated with clinicopathological characteristics rep …

2022年7月28日 · Background and Objectives: We aim to compare the diagnostic performance of Protein induced by vitamin K absence-II (PIVKA-II), a biomarker for hepatocellular carcinoma (HCC), and alpha-fetoprotein (AFP) in differentiating HCC and non-malignant high-risk (NMHR) groups and to determine their cut-off values.

2017年3月20日 · Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC). Limited data are available about its utility in discriminating neoplastic from regenerative nodules at ultrasonography (US) evaluation in …

Multi‐center study showed the satisfactory diagnostic performance of PIVKA‐II in hepatocellular carcinoma. PIVKA‐II has excellent specificity in distinguishing benign liver diseases. The distribution of PIVKA‐II among chronic liver diseases. 1. INTRODUCTION.

Protein induced by vitamin K absence or antagonist II (PIVKA-II) is a well-accepted biomarker for diagnosing hepatocellular carcinoma (HCC). Although nonspecific increase of PIVKA-II has been reported, real-world evidence remains scarce.

Serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) is a promising biomarker for hepatocellular carcinoma (HCC) surveillance. To identify the contributing factors related to the abnormal elevation of PIVKA-II level and assess ...